首页> 美国卫生研究院文献>International Journal of Nanomedicine >Polymeric nanoparticle-based delivery of microRNA-199a-3p inhibits proliferation and growth of osteosarcoma cells
【2h】

Polymeric nanoparticle-based delivery of microRNA-199a-3p inhibits proliferation and growth of osteosarcoma cells

机译:基于聚合纳米颗粒的microRNA-199a-3p抑制骨肉瘤细胞的增殖和生长

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Our prior screening of microRNAs (miRs) identified that miR-199a-3p expression is reduced in osteosarcoma cells, one of the most common types of bone tumor. miR-199a-3p exhibited functions of tumor cell growth inhibition, suggesting the potential application of miR-199a-3p as an anticancer agent. In the study reported here, we designed and developed a lipid-modified dextran-based polymeric nanoparticle platform for encapsulation of miRs, and determined the efficiency and efficacy of delivering miR-199a-3p into osteosarcoma cells. In addition, another potent miR, let-7a, which also displayed tumor suppressive ability, was selected as a candidate miR for evaluation. Fluorescence microscopy studies and real-time polymerase chain reaction results showed that dextran nanoparticles could deliver both miR-199a-3p and let-7a into osteosarcoma cell lines (KHOS and U-2OS) successfully. Western blotting analysis and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays demonstrated that dextran nanoparticles loaded with miRs could efficiently downregulate the expression of target proteins and effectively inhibit the growth and proliferation of osteosarcoma cells. These results demonstrate that a lipid-modified dextran-based polymeric nanoparticle platform may be an effective nonviral carrier for potential miR-based anticancer therapeutics.
机译:我们先前对microRNA(miRs)的筛选确定了骨肉瘤细胞(一种最常见的骨肿瘤类型)中miR-199a-3p表达降低。 miR-199a-3p表现出抑制肿瘤细胞生长的功能,暗示了miR-199a-3p作为抗癌剂的潜在应用。在这里报道的研究中,我们设计和开发了脂质修饰的基于葡聚糖的聚合物纳米颗粒平台,用于miR的封装,并确定了将miR-199a-3p传递至骨肉瘤细胞的效率和功效。此外,还选择了另一种有效的miR,let-7a(也显示出肿瘤抑制能力)作为候选miR进行评估。荧光显微镜研究和实时聚合酶链反应结果表明,右旋糖酐纳米颗粒可以成功地将miR-199a-3p和let-7a均递送至骨肉瘤细胞系(KHOS和U-2OS)。 Western印迹分析和3-(4,5-二甲基噻唑-2-基)-2,5-二苯基四唑溴化盐(MTT)分析表明,载有miRs的右旋糖酐纳米颗粒可有效下调靶蛋白的表达并有效抑制其生长和增殖骨肉瘤细胞。这些结果表明,脂质修饰的基于葡聚糖的聚合物纳米粒子平台可能是潜在的基于miR的抗癌治疗药物的有效非病毒载体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号